Kent Snyder
Director/Board Member chez SENOMYX INC.
Profil
Kent Snyder is currently a Director at Senomyx, Inc. and a Director at VentiRx Pharmaceuticals, Inc. He was previously an Independent Director at Santarus, Inc. from 2011 to 2014.
He also served as a Director at BioAtla, Inc. and as the President-Global Commercial Operations at Agouron Pharmaceuticals LLC from 1991 to 2001.
Mr. Snyder holds an MBA from Rockhurst University and an undergraduate degree from the University of Kansas.
Postes actifs de Kent Snyder
Sociétés | Poste | Début |
---|---|---|
SENOMYX INC. | Director/Board Member | - |
VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | Director/Board Member | - |
Anciens postes connus de Kent Snyder
Sociétés | Poste | Fin |
---|---|---|
Santarus, Inc.
Santarus, Inc. Pharmaceuticals: MajorHealth Technology Santarus, Inc. operates as a biopharmaceutical company. The company was founded on December 6, 1996 and is headquartered in Bridgewater, NJ. | Director/Board Member | 02/01/2014 |
Agouron Pharmaceuticals LLC
Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/10/2001 |
BIOATLA, INC. | Director/Board Member | - |
Formation de Kent Snyder
Rockhurst University | Masters Business Admin |
University of Kansas | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
BIOATLA, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Agouron Pharmaceuticals LLC
Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Health Technology |
Senomyx, Inc.
Senomyx, Inc. Food: Specialty/CandyConsumer Non-Durables Senomyx, Inc. engages in the development and commercialization of flavor ingredients for the packaged food, beverage, and ingredient supply industries. It develops high intensity sweeteners, savory flavors, bitter taste blockers, and cooling agents. The company was founded by Paul A. Grayson, Lubert Stryer, Yon Chien Tsien, Denis Baylor, Harold McGee, and Charles Zuker on September 16, 1998 and is headquartered in San Diego, CA. | Consumer Non-Durables |
Santarus, Inc.
Santarus, Inc. Pharmaceuticals: MajorHealth Technology Santarus, Inc. operates as a biopharmaceutical company. The company was founded on December 6, 1996 and is headquartered in Bridgewater, NJ. | Health Technology |
VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | Health Technology |